Objective
In the aging society, disease burden, such as degenerative diseases and cancer are rising while drug development successes are limited, due to high drug failure rates in the transition from animal experimentation to human patients. This demands re-thinking of the currently used models. Advances in stem cell biology and microfluidics have created new human organ models. These models are neither fully understood, nor fully mimicking the complexity of the tissue. With this new ability to build human stem cell-based models, we have a responsibility to drive these models to implementation – aiming to replace animal experimentation and provide next generation patient avatars for precision medicine.
TOP-GUT combines cutting-edge basic and translational science with an outstanding program of education to unleash the full potential of new human organ models, specifically patient-derived organoids and organ-on-chip devices. TOP-GUT will focus on the gastrointestinal (GI) tract, which is the bodies second largest interface with the environment. It is medically highly relevant not only as a major site of cancer development, as target of infectious agents, and as site of inflammatory diseases, but also as one of the major organs for drug uptake and relevance in toxicology. TOP-GUT aims to significantly contribute to our understanding of the current GI models, establish new tools and protocols for more complex GI models, and advance the use of GI models for personalised medicine. In addition, TOP-GUT will address ethical and legal issues to foster acceptance and implementation of the GI models. TOP-GUT will build a solid European network to cooperate, standardize and push GI models into applications, bringing together academia and industry. Together, TOP-GUT educates the next generation of researchers to become new leaders in the field and to drive the implementation of new stem cell based human models to replace animal experimentation in academia and industry.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
10623 Berlin
Germany
See on map
Participants (7)
10117 Berlin
See on map
1165 Kobenhavn
See on map
3584 CS Utrecht
See on map
4200-135 Porto
See on map
13347 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2342 DH Oegstgeest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
0313 Oslo
See on map
Partners (13)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6500 Bellinzona
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2740-122 Porto Salvo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3732 HJ De Bilt
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
13355 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8952 Schlieren
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4070 Basel
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
76344 Eggenstein-Leopoldshafen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2970 Hoersholm
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
53100 Siena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3584 CX Utrecht
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
0213 Oslo
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6900 Lugano
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4099-002 Porto
See on map